Lg Chemical Ltd.

Oscotec Inc.

Genosco

Lucky Limited

Yuhan Corporation

Korea Advanced Institute of Science and Technology

Lg Life Sciences, Limited

Jong Sung Koh

Jaekyoo Lee

Ho-Juhn Song

In Y Lee

Jong Hyun Kim

Ho Il Choi

Sung Chun Kim

Seong Gu Ro

Heungsik Yoon

Nakyen Choy

Young Chan Son

Tae Hwan Kwak

Hyun Il Lee

Hyun Ho Chung

Won Hee Jung

Se-Won Kim

Sun Hwa Lee

In Ae Ahn

Sang Soo Kim

You Seung Shin

Jang-Sik Choi

Hyun Sung Kim

Tae Saeng Choi

Chang Sun Lee

Chi Hyo Park

Jaesang Lee

Kwi Hwa Kim

Jin Ho Lee

Jung-ho Kim

Jung-Ho Kim

Byung-Chul Suh

Hong Woo Kim

Paresh Salgaonkar

Hee Kyu Lee

Dong Sik Jung

Shin Wu Jeong

Jung Kwon Yoo

Sunhwa Chang

Chung Ryeol Kim

Youngsam Kim

Sun-Hee Lim

Hae-Jun Hwang

In Yong Lee

Ji Young Kim

Hye Jin Kim

Jae Kwang Kim

Se Ryung Kim

Chang-Seok Lee

Hee Han

Chang Soon Lee

Min-Jung Kim

Chi Hoon Park

Ki Dong Koo

Hyeon Joo Yim

Sung Ho Kim

Dong-Sik Jung

Sungsub Kim

Se Won Kim

Sang Yong Hong

Yung-Geun Choi

Sung-Ho Park

Kyoung-Hee Kim

Geun Tae Kim

Kwang Yul Moon

Wonhee Jung

Kwang-Yul Moon

Sang Woong Kim

Tae-Im Lee

Kyung Duk Moon

Dongchul Lim

Young Hoon Oh

Seong Cheol Bu

Gwong-Cheung Hur

Zi-Ho Yeom

Eunho Lee

Dong-Jun Yeo

Tae-im Lee

Yung-geun Choi

Ik-hwan Han

You Seong Shin

Ki Won Park

Oh Hwan Kwon

Chung Mi Kim

Paresh Devidas Salgaonkar

Ik-Hwan Han

Hee Oon Han

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

Compounds and compositions for modulating EGFR mutant kinase activities

Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I). 

Substituted pyrimidine compounds and their use as SYK inhibitors

Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

Kinase inhibitors

The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

Novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV(DPP-IV) include those of the following formula (1) or pharmaceutically acceptable salt thereof: wherein A is a substituted or unsubstituted 1,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine, 5,6 -dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine, 4,5-dihydro-7H-isooxazolo[3,4-c]pyridine, 3,4 -dihydroisoquinoline, 5,8-dihydropyrido[3,4-d]pyrimidine, or 6,7 -dihydro[1,3]thiazolo[4,5,c]pyridine, and B is a substituted or unsubstituted piperidin-2-one, morpholin-3-one, oxazolidin-2-one, pyrrolidin-2-one, or 1,5-dihydro-pyrrol-2-one. Methods of preparing the novel inhibitory compounds of formula (1) and pharmaceutical compositions containing the same as an active agent are disclosed.

Dipeptidyl Peptidase-IV inhibiting compounds, method of preparing the same, and pharmaceutical compositions containing the same as an active agent

The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1): and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

The present invention relates to novel hydantoin compounds represented by formula (I) which shows an inhibitory activity against farnesyl transferase, and thus can be used as an anti-cancer agent, or pharmaceutically acceptable salts thereof, in which R , R , R and R are as defined in the present application. The present invention also relates to a process for preparation of the compound of formula (I), and to an anti-cancer composition comprising the compound of formula (I) as an active ingredient.

Hydantoin compounds and methods related thereto

The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n,and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

The present invention relates to a novel compound of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof which is an irreversible HIV protease inhibitor; a process for the preparation thereof; and a pharmaceutical composition containing the compound as an active ingredient which is useful for treating or preventing diseases caused by HIV infection. ##STR1##

Irreversible HIV protease inhibitor having an anti-aids activity and

Cis-epoxide compounds of formula (I-3) and pharmaceutically acceptable salts, hydrates and solvates thereof: ##STR1## wherein: R.sup.1 is a cycloalkyl, or arly-substituted lower alkyl group;

Irreversible HIV protease inhibitors, intermediates, compositions and

Growing community of inventors

Daejeon, South Korea

Jong Sung Koh